{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:32Z","timestamp":1790996612894,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40265-015-0377-y","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T08:20:57Z","timestamp":1426839657000},"page":"487-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["An Update on Pharmacological, Pharmacokinetic Properties and Drug\u2013Drug Interactions of Rotigotine Transdermal System in Parkinson\u2019s Disease and Restless Legs Syndrome"],"prefix":"10.1007","volume":"75","author":[{"given":"Jan-Peer","family":"Elshoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willi","family":"Cawello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Otto","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Mathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"issue":"1","key":"377_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","volume":"62","author":"MC Rijk de","year":"1997","unstructured":"de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"11","key":"377_CR2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Eeden Van Den","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol. 2003;157(11):1015\u201322.","journal-title":"Am J Epidemiol."},{"issue":"1","key":"377_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","volume":"37","author":"Y Smith","year":"2012","unstructured":"Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson\u2019s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology. 2012;37(1):213\u201346.","journal-title":"Neuropsychopharmacology."},{"issue":"6","key":"377_CR4","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","volume":"26","author":"O Rascol","year":"2011","unstructured":"Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson\u2019s disease therapeutics. Mov Disord. 2011;26(6):1072\u201382.","journal-title":"Mov Disord."},{"issue":"7617","key":"377_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/bmj.39289.437454.AD","volume":"335","author":"CE Clarke","year":"2007","unstructured":"Clarke CE. Parkinson\u2019s disease. BMJ. 2007;335(7617):441\u20135.","journal-title":"BMJ."},{"issue":"12","key":"377_CR6","first-page":"2046","volume":"74","author":"SS Rao","year":"2006","unstructured":"Rao SS, Hofmann LA, Shakil A. Parkinson\u2019s disease: diagnosis and treatment. Am Fam Physician. 2006;74(12):2046\u201354.","journal-title":"Am Fam Physician."},{"issue":"4","key":"377_CR7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"377_CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/14737175.8.2.297","volume":"8","author":"LO Ramig","year":"2008","unstructured":"Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson\u2019s disease. Expert Rev Neurother. 2008;8(2):297\u2013309.","journal-title":"Expert Rev Neurother."},{"issue":"23","key":"377_CR9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3109\/09638288.2014.883442","volume":"36","author":"J Simpson","year":"2014","unstructured":"Simpson J, Lekwuwa G, Crawford T. Predictors of quality of life in people with Parkinson\u2019s disease: evidence for both domain specific and general relationships. Disabil Rehabil. 2014;36(23):1964\u201370.","journal-title":"Disabil Rehabil."},{"issue":"2","key":"377_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.25664","volume":"29","author":"GW Duncan","year":"2014","unstructured":"Duncan GW, Khoo TK, Yarnall AJ, O\u2019Brien JT, Coleman SY, Brooks DJ, et al. Health-related quality of life in early Parkinson\u2019s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195\u2013202.","journal-title":"Mov Disord."},{"issue":"3","key":"377_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson\u2019s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308\u201312.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"Suppl 2","key":"377_CR12","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1007\/s00415-010-5719-9","volume":"257","author":"E Hametner","year":"2010","unstructured":"Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257(Suppl 2):S268\u201375.","journal-title":"J Neurol."},{"key":"377_CR13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/NDT.S32302","volume":"9","author":"DJ Pedrosa","year":"2013","unstructured":"Pedrosa DJ, Timmermann L. Review: management of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2013;9:321\u201340.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"6 Suppl 1","key":"377_CR14","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/NRL.0b013e31823966e3","volume":"17","author":"MC Rodriguez-Oroz","year":"2011","unstructured":"Rodriguez-Oroz MC, Marin C, de Fabregues O. Continuous dopaminergic stimulation: clinical aspects and experimental bases. Neurologist. 2011;17(6 Suppl 1):S30\u20137.","journal-title":"Neurologist."},{"issue":"6","key":"377_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneurol.2010.55","volume":"6","author":"C Trenkwalder","year":"2010","unstructured":"Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010;6(6):337\u201346.","journal-title":"Nat Rev Neurol."},{"issue":"2","key":"377_CR16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archinte.164.2.196","volume":"164","author":"K Berger","year":"2004","unstructured":"Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164(2):196\u2013202.","journal-title":"Arch Intern Med."},{"issue":"Suppl","key":"377_CR17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1389-9457(02)00140-5","volume":"3","author":"RP Allen","year":"2002","unstructured":"Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med. 2002;3(Suppl):S3\u20137.","journal-title":"Sleep Med."},{"issue":"Suppl 3","key":"377_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1468-1331.2006.01586.x","volume":"13","author":"JW Winkelman","year":"2006","unstructured":"Winkelman JW. Considering the causes of RLS. Eur J Neurol. 2006;13(Suppl 3):8\u201314.","journal-title":"Eur J Neurol."},{"key":"377_CR19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/WCO.0000000000000117","volume":"27","author":"D Garcia-Borreguero","year":"2014","unstructured":"Garcia-Borreguero D, Williams AM. An update on restless legs syndrome (Willis Ekbom disease): clinical features, pathogenesis and treatment. Curr Opin Neurol. 2014;27:493\u2013501.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"377_CR20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","volume":"8","author":"D Garcia-Borreguero","year":"2007","unstructured":"Garcia-Borreguero D, Allen RP, Kohnen R, Hogl B, Trenkwalder C, Oertel W, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8(5):520\u201330.","journal-title":"Sleep Med."},{"issue":"2","key":"377_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00415-009-5299-8","volume":"257","author":"B Hogl","year":"2010","unstructured":"Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257(2):230\u20137.","journal-title":"J Neurol."},{"issue":"7","key":"377_CR22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Hogl B, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675\u201384.","journal-title":"Sleep Med."},{"issue":"4","key":"377_CR23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","volume":"34","author":"JP Elshoff","year":"2012","unstructured":"Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966\u201378.","journal-title":"Clin Ther."},{"issue":"1","key":"377_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","volume":"379","author":"D Scheller","year":"2009","unstructured":"Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73\u201386.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"377_CR25","doi-asserted-by":"crossref","unstructured":"Millan M, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential action of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. JEPT. 2002;303:791\u2013804.","DOI":"10.1124\/jpet.102.039867"},{"issue":"2\u20133","key":"377_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(88)90309-3","volume":"146","author":"J Weide Van der","year":"1988","unstructured":"Van der Weide J, Tendijck ME, Tepper PG, De Vries JB, Dubocovich ML, Horn AS. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol. 1988;146(2\u20133):319\u201326.","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"377_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0014-2999(86)90037-3","volume":"125","author":"J Weide Van der","year":"1986","unstructured":"Van der Weide J, De Vries JB, Tepper PG, Horn AS. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J Pharmacol. 1986;125(2):273\u201382.","journal-title":"Eur J Pharmacol."},{"issue":"1","key":"377_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(89)90677-8","volume":"166","author":"W Timmerman","year":"1989","unstructured":"Timmerman W, Dubocovich ML, Westerink BH, De Vries JB, Tepper PG, Horn AS. The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine. Eur J Pharmacol. 1989;166(1):1\u201311.","journal-title":"Eur J Pharmacol."},{"issue":"10","key":"377_CR29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00702-008-0102-z","volume":"115","author":"WJ Schmidt","year":"2008","unstructured":"Schmidt WJ, Lebsanft H, Heindl M, Gerlach M, Gruenblatt E, Riederer P, et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm. 2008;115(10):1385\u201392.","journal-title":"J Neural Transm."},{"issue":"2","key":"377_CR30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.expneurol.2009.07.011","volume":"219","author":"KA Stockwell","year":"2009","unstructured":"Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol. 2009;219(2):533\u201342.","journal-title":"Exp Neurol."},{"issue":"10","key":"377_CR31","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1124\/dmd.109.027383","volume":"37","author":"W Cawello","year":"2009","unstructured":"Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37(10):2055\u201360.","journal-title":"Drug Metab Dispos."},{"issue":"10","key":"377_CR32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00003088-200746100-00003","volume":"46","author":"W Cawello","year":"2007","unstructured":"Cawello W, Wolff HM, Meuling WJ, Horstmann R, Braun M. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet. 2007;46(10):851\u20137.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"377_CR33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.2008.143","volume":"84","author":"M Malik","year":"2008","unstructured":"Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M, et al. Thorough QT\/QTc study in patients with advanced Parkinson\u2019s disease: cardiac safety of rotigotine. Clin Pharmacol Ther. 2008;84(5):595\u2013603.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"377_CR34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.WNF.0000228179.83335.65","volume":"29","author":"T Babic","year":"2006","unstructured":"Babic T, Boothmann B, Polivka J, Rektor I, Boroojerdi B, Hack HJ, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol. 2006;29(4):238\u201342.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"377_CR35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40261-013-0150-5","volume":"34","author":"W Cawello","year":"2014","unstructured":"Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. 2014;34(2):95\u2013105.","journal-title":"Clin Drug Investig."},{"key":"377_CR36","doi-asserted-by":"crossref","unstructured":"Cawello W, Kim SR, Braun M, Elshoff J-P, Masahiro T, Ikeda J, et al. Pharmacokinetics, safety and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple dose administration. Eur J Drug Metab Pharmacokinet. 2015 (in press).","DOI":"10.1007\/s13318-015-0273-6"},{"key":"377_CR37","doi-asserted-by":"crossref","unstructured":"Kim B-H, Yu K-S, Jang I-J, Soo Lim K, Kim J-R, Elshoff J-P, et al. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy Korean volunteers. Clin Ther. 2015 (in press).","DOI":"10.1016\/j.clinthera.2015.01.013"},{"issue":"3","key":"377_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13318-013-0153-x","volume":"39","author":"W Cawello","year":"2014","unstructured":"Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39(3):155\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"1","key":"377_CR39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2125.2011.04053.x","volume":"73","author":"W Cawello","year":"2012","unstructured":"Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, Braun M. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol. 2012;73(1):46\u201354.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 2","key":"377_CR40","first-page":"42","volume":"13","author":"W Cawello","year":"2006","unstructured":"Cawello W, Elshoff JP, Boekens H, Braun M. Characteristics of rotigotine elimination after patch removal. Eur J Neurol. 2006;13(Suppl 2):42.","journal-title":"Eur J Neurol."},{"issue":"6","key":"377_CR41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320.","journal-title":"Lancet Neurol."},{"issue":"2","key":"377_CR42","first-page":"S288","volume":"26","author":"J Whitesides","year":"2011","unstructured":"Whitesides J, Cawello W, Woltering F, Boroojerdi B, Poewe W. Stable plasma levels of rotigotine following transdermal patch removal and new patch application during long-term treatment of patients with advanced Parkinson\u2019s disease. Mov Disord. 2011;26(2):S288.","journal-title":"Mov Disord."},{"issue":"2","key":"377_CR43","first-page":"S365","volume":"26","author":"J Whitesides","year":"2011","unstructured":"Whitesides J, Cawello W, Braun M, Fichtner A, Oertel WH. Stability of rotigotine plasma levels during long-term transdermal application for patients with idiopathic restless legs syndrome. Mov Disord. 2011;26(2):S365.","journal-title":"Mov Disord."},{"issue":"9","key":"377_CR44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0091270009338481","volume":"49","author":"M Braun","year":"2009","unstructured":"Braun M, Cawello W, Andreas JO, Boekens H, Horstmann R. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa\/carbidopa. J Clin Pharmacol. 2009;49(9):1047\u201355.","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"377_CR45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.2008.03334.x","volume":"67","author":"M Braun","year":"2009","unstructured":"Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol. 2009;67(2):209\u201315.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"377_CR46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2125.2009.03468.x","volume":"68","author":"M Braun","year":"2009","unstructured":"Braun M, Elshoff JP, Andreas JO, Muller LI, Horstmann R. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br J Clin Pharmacol. 2009;68(3):386\u201394.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"377_CR47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cpdd.78","volume":"3","author":"JP Elshoff","year":"2014","unstructured":"Elshoff JP, Cawello W, Andreas JO, Braun M. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine. Clin Pharmacol Drug Devel. 2014;3(3):187\u201393.","journal-title":"Clin Pharmacol Drug Devel."},{"key":"377_CR48","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence CPMP\/EWP\/QWP\/1401\/98 Rev. 1. 20 January 2010. Available online at URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf . Accessed 27 Feb 2015."},{"issue":"4","key":"377_CR49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1345\/aph.18003","volume":"33","author":"JA Barone","year":"1999","unstructured":"Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429\u201340.","journal-title":"Ann Pharmacother."},{"issue":"7","key":"377_CR50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","volume":"7","author":"C Trenkwalder","year":"2008","unstructured":"Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(7):595\u2013604.","journal-title":"Lancet Neurol."},{"issue":"4","key":"377_CR51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272\u20136.","journal-title":"Neurology."},{"issue":"5","key":"377_CR52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2165\/00003495-198224050-00002","volume":"24","author":"RN Brogden","year":"1982","unstructured":"Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24(5):360\u2013400.","journal-title":"Drugs."},{"issue":"6","key":"377_CR53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00002826-198612000-00003","volume":"9","author":"JD Parkes","year":"1986","unstructured":"Parkes JD. Domperidone and Parkinson\u2019s disease. Clin Neuropharmacol. 1986;9(6):517\u201332.","journal-title":"Clin Neuropharmacol."},{"issue":"Suppl I","key":"377_CR54","first-page":"1","volume":"4","author":"K Hansen","year":"2007","unstructured":"Hansen K, Braun M, Horstmann R, Cawello W, Schaffenecker U. Low drug drug interaction potential of rotigotine. Neurodegenerative Dis. 2007;4(Suppl I):1\u2013350.","journal-title":"Neurodegenerative Dis."},{"issue":"7","key":"377_CR55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","volume":"46","author":"B Boroojerdi","year":"2010","unstructured":"Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson\u2019s disease and restless legs syndrome. Drugs Today (Barc). 2010;46(7):483\u2013505.","journal-title":"Drugs Today (Barc)."},{"issue":"8","key":"377_CR56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","volume":"25","author":"M Sanford","year":"2011","unstructured":"Sanford M, Scott LJ. Rotigotine transdermal patch. A review of its use in the treatment of Parkinson\u2019s disease. CNS Drugs. 2011;25(8):699\u2013719.","journal-title":"CNS Drugs"},{"issue":"5","key":"377_CR57","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676\u201382.","journal-title":"Arch Neurol."},{"issue":"16","key":"377_CR58","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398\u2013404.","journal-title":"Mov Disord."},{"issue":"16","key":"377_CR59","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262\u20137.","journal-title":"Neurology."},{"issue":"11","key":"377_CR60","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/mds.23157","volume":"25","author":"WA Hening","year":"2010","unstructured":"Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675\u201383.","journal-title":"Mov Disord."},{"issue":"9","key":"377_CR61","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00702-013-1001-5","volume":"120","author":"N Giladi","year":"2013","unstructured":"Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson\u2019s disease. J Neural Transm. 2013;120(9):1321\u20139.","journal-title":"J Neural Transm."},{"issue":"8","key":"377_CR62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(11)70127-2","volume":"10","author":"W Oertel","year":"2011","unstructured":"Oertel W, Trenkwalder C, Benes H, Ferini-Strambi L, Hogl B, Poewe W, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10(8):710\u201320.","journal-title":"Lancet Neurol."},{"issue":"2","key":"377_CR63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.parkreldis.2011.10.010","volume":"18","author":"SR Schreglmann","year":"2012","unstructured":"Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207\u20139.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"377_CR64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2011.01.010","volume":"17","author":"C Hinnell","year":"2011","unstructured":"Hinnell C, Hulse N, Martin A, Samuel M. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. Parkinsonism Relat Disord. 2011;17(4):295\u20136.","journal-title":"Parkinsonism Relat Disord."},{"key":"377_CR65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JPD-130320","volume":"4","author":"AP Nicholas","year":"2014","unstructured":"Nicholas AP, et al. A randomized study of rotigotine dose response on \u2018off\u2019 time in advanced Parkinson\u2019s disease. J Parkinsons Dis. 2014;4:361\u201373.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"377_CR66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139.","journal-title":"Mov Disord."},{"issue":"5","key":"377_CR67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.parkreldis.2012.01.008","volume":"18","author":"LW Elmer","year":"2012","unstructured":"Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson\u2019s disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012;18(5):488\u201393.","journal-title":"Parkinsonism Relat Disord."},{"issue":"9","key":"377_CR68","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.sleep.2010.02.014","volume":"11","author":"WH Oertel","year":"2010","unstructured":"Oertel WH, Benes H, Garcia-Borreguero D, Hogl B, Poewe W, Montagna P, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848\u201356.","journal-title":"Sleep Med."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0377-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0377-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0377-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:08:45Z","timestamp":1717801725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0377-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0377-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}